CHEOY:OTC-Cochlear Limited (USD)

COMMON STOCK | Medical Devices | OTC

Last Closing Price

USD 87.27

Change

0.00 (0.00)%

Market Cap

USD 10.93B

Volume

1.87K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SNNUF Smith & Nephew plc

+0.77 (+3.58%)

USD19.07B 41.99 23.99
MCRPF MicroPort Scientific Corporati..

N/A

USD13.15B 219.70 53.08
GGNDF GN Store Nord A/S

N/A

USD11.89B 58.49 4.40
GNNDY GN Store Nord A/S

+6.80 (+2.56%)

USD11.40B 56.82 4.40
CHEOF Cochlear Limited

N/A

USD11.24B 45.76 23.12
MEDGF Medacta Group SA

+8.90 (+7.77%)

USD2.57B 51.41 33.62
NHNKY Nihon Kohden Corporation

N/A

USD2.43B 19.71 0.09
NHNKF Nihon Kohden Corporation

N/A

USD2.11B 24.60 -78.50
DWRKF Drägerwerk AG & Co. KGaA

N/A

USD1.93B 58.71 N/A
DGWPF Drägerwerk AG & Co. KGaA

N/A

USD1.69B 7.76 2.63

ETFs Containing CHEOY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.32% 40% F 51% F
Dividend Return 0.61% 50% F 14% F
Total Return 18.93% 40% F 51% F
Trailing 12 Months  
Capital Gain 48.62% 39% F 46% F
Dividend Return 0.77% 50% F 6% F
Total Return 49.39% 40% F 46% F
Trailing 5 Years  
Capital Gain 112.85% 63% D 69% D+
Dividend Return 9.61% 75% C 35% F
Total Return 122.47% 63% D 69% D+
Average Annual (5 Year Horizon)  
Capital Gain 13.34% 39% F 56% F
Dividend Return 1.34% 89% B+ 42% F
Total Return 14.68% 39% F 55% F
Risk Return Profile  
Volatility (Standard Deviation) 20.98% 94% A 77% C+
Risk Adjusted Return 69.94% 95% A 91% A-
Market Capitalization 10.93B 95% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 51.97 35% F 15% F
Price/Book Ratio 9.06 42% F 17% F
Price / Cash Flow Ratio -69.28 91% A- 93% A
EV/EBITDA 23.12 50% F 18% F
Management Effectiveness  
Return on Equity -13.06% 69% D+ 32% F
Return on Invested Capital 18.70% 65% D 82% B-
Return on Assets 7.04% 93% A 90% A-
Debt to Equity Ratio 5.70% 48% F 71% C-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.35 67% D+ 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector